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Abstract
Introduction: Sexually transmitted diseases (STDs) are increasing in the United States. Pregnant 
women and infants are susceptible to serious STD-related sequelae; however, some STDs can be 
cured during pregnancy with appropriate, timely screening.
Methods: We used data from the 2011–2015 National Survey of Family Growth to examine STD 
testing (in the past 12 months) among women who were pregnant in the past 12 months (n=1,155). 
In bivariate and multivariable analyses, we examined associations between demographics, health 
care access and two outcome variables – receipt of chlamydia test and receipt of other STD test.
Results: Among women who were pregnant in the past 12 months, 48% reported receiving a 
chlamydia test and 54% reported that they received a STD test other than chlamydia in the past 12 
months. In adjusted analyses, non-Hispanic black women were more likely to receive a chlamydia 
test (aOR=2.82, 1.86–4.26) and other STD test (aOR=2.43, 1.58–3.74) than non-Hispanic white 
women. Women living in a metropolitan statistical area but not the principal city were less likely 
to report chlamydia (aOR=0.62, 0.44–0.86) and other STD testing (aOR=0.57, 0.40–0.81) than 
women living in a principal city. Women born outside of the U.S. were significantly less likely to 
have received a chlamydia test (aOR=0.35, 0.19–0.64) or other STD test (aOR=0.34, 0.20–0.58) 
while those who had received prenatal care were more likely to receive a chlamydia test 
(aOR=2.10, 1.35–3.28) or other STD test (aOR=2.32, 1.54–3.49).
Conclusions: Our findings suggest that interventions are needed to increase adherence to 
recommended STD screenings during pregnancy.
Summary
STD screening during pregnancy is important to prevent adverse pregnancy outcomes. Using 
national survey data from the United States, we found that many women are not receiving 
recommended STD screenings during pregnancy. Interventions may be needed to increase 
awareness of national STD testing recommendations among pregnant women and health care 
providers.
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Introduction
In 2017, several nationally reportable sexually transmitted diseases (STD) in the United 
States (U.S.) – chlamydia, gonorrhea, primary and secondary (P&S) syphilis, and congenital 
syphilis – increased for the fourth consecutive year.1 Pregnant women and infants are among 
the subpopulations that may experience the most significant complications of STD. Among 
women, the 2017 STD rates per 100,000 population were 682.9 for chlamydia, 140.3 for 
gonorrhea and 2.3 for P&S syphilis.1 Additionally, 23.3 congenital syphilis cases per 
100,000 live births were reported in 2017 with cases increasing annually since 2012.1 The 
prevalence of STDs among pregnant women, especially younger women, can be high. A 
survey from 2009–2011 of pregnant women in five U.S. states found that 3.3% reported 
having chlamydia, gonorrhea, syphilis or trichomoniasis during their pregnancy.2 Women 
who had low incomes, lacked health insurance and had their first prenatal care visit 
subsequent to their first trimester were significantly more likely to report a STD during 
pregnancy.2 A review of studies focusing on pregnancy in teens found that STD positivity 
ranged from 19–39% across the studies.3 The STDs included in the overall positivity totals 
varied depending on the study but included chlamydia, gonorrhea, or trichomoniasis.3
Acquiring a STD during pregnancy is especially problematic as many STDs can be 
asymptomatic and they can result in a number of complications.4 Vertical transmission of 
some STDs during pregnancy can cause significant sequelae, such as adverse pregnancy 
outcomes, low birth weight, blindness, neurological and developmental issues, and stillbirth.
5–7
 However, congenital STDs are often preventable with appropriate access to, and use of, 
health services including STD testing and treatment. Thus, the U.S. Centers for Disease 
Control and Prevention (CDC) recommends screening pregnant women for several STDs 
with the goal of preventing perinatal infections and associated complications. At the first 
prenatal visit or early in pregnancy, the CDC recommends that all pregnant women should 
be tested for syphilis, and pregnant women < 25 years, or older pregnant women who are at 
increased risk for STDs, should be tested for chlamydia and gonorrhea.8 For women who 
live in areas with high levels of syphilis or who are at high risk for acquiring syphilis, CDC 
recommends additional screening around 28 weeks (or early in the third trimester) and at 
delivery.8 Prenatal syphilis screening is extremely important to prevent congenital syphilis, 
and a recent assessment of U.S. state policies found that 45 states (out of the 50 states plus 
the District of Columbia) have requirements for prenatal syphilis screening.9 The majority of 
states (84%) required syphilis screening at the first prenatal visit and 33% required screening 
in the third trimester either for all pregnant women or those at high risk for syphilis.9
Previous U.S. studies focusing on STD testing or screening among pregnant women using 
health insurance claims data or surveys of providers have been helpful; 10–13 however, they 
have had some limitations. The U.S. health care system is comprised of private and public 
health insurers with Medicaid serving as the public insurance option for non-elderly, 
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impoverished persons. Medicaid is a federal-state partnership and income-based eligibility 
can vary by state. In 2013, 13.3% of persons were uninsured, 64.1% had private insurance, 
17.5% had Medicaid and the rest had Medicare (public health insurance for elderly persons) 
or military insurance.14 Studies using health insurance claims data typically do not include 
data from all health plans or, when using Medicaid data, from all states. These studies also 
do not include uninsured women and have typically limited analyses to women who had 
received prenatal care. Some women who are uninsured may not meet the Medicaid 
eligibility requirements, such as being a legal U.S. resident, and others may not be aware 
that their pregnancy may qualify them for Medicaid. Even among women with health 
insurance, some receive late or no prenatal care—ranging from 2.7% of those with private 
insurance to 8.6% of women with Medicaid in 2016; among women who self-paid for 
medical care, 19.8% received late or no prenatal care.15 To assess provider practices, surveys 
are often used as they can capture more information from a larger geographic area than 
medical chart reviews. However, provider surveys are limited in that they ask providers to 
generalize their STD testing and screening practices across groups of patients so they may 
not represent all clinical encounters.
Given recent increases in STDs and the gaps in the existing literature, it is important to 
assess STD-related testing received by all U.S. pregnant women, including those who are 
uninsured. Research has found that persons who lack health insurance are less likely to 
report having a usual place for medical care and seeing a medical provider.16 Thus, we used 
data from a U.S. national survey of reproductive aged women to assess receipt of STD 
testing among women who were currently pregnant or had been pregnant in the past 12 
months. We also aimed to determine if receipt of STD testing among pregnant women 
differed by demographics and health care access and use.
Methods
Data
We used data from women who participated in the 2011–2015 National Survey of Family 
Growth (NSFG). NSFG is a national probability survey of women and men aged 15–44 
years and is representative of the US household population. The 2011–2015 NSFG included 
11,300 women with a 72% response rate for women. Details on sampling for the NSFG have 
been published elsewhere.17 NSFG used both computer assisted personal interview (CAPI) 
and audio computer assisted self-interview (ACASI) for data collection. The survey was 
approved by the National Center for Health Statistics research ethics review board; all 
respondents provided informed consent with assent and parental consent provided for those 
15–17 years old. During the CAPI, women provided information on all pregnancies 
including timing. For this analysis, we included only women who reported a pregnancy in 
the past 12 months or who were pregnant at interview or (n=1,155).
Measures
We included two dependent variables collected via ACASI: 1) received chlamydia test in 
past 12 months, and 2) received STD test other than chlamydia (gonorrhea, syphilis or 
herpes were provided as examples) in past 12 months. We recoded “don’t know” responses 
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as missing. “Don’t know” responses represented less than one percent of responses. Our 
independent variables were collected via CAPI and included demographics and measures of 
health care access and use. Our primary pregnancy variable was whether the respondent was 
pregnant within 12 months of interview (pregnant in past 12 months). Given that CDC 
screening recommendations for pregnant women stress screening in early pregnancy or the 
first prenatal visit, we also calculated pregnancy-postpartum status at the time of interview 
(n=1,041) using 3 groups: 1) early pregnancy (first trimester); 2) late pregnancy (second and 
third trimester); and 3) postpartum (<=6 months from delivery). Women who had delivered 
> 6 months were not included. Demographic variables consisted of: 1) race/ethnicity 
(Hispanic, non-Hispanic black, non-Hispanic white, non-Hispanic other); 2) poverty income 
ratio, which is the ratio of household income to the federal poverty level and was coded 
using the Medicaid expansion cutoff (0–133%, 134% or higher); 3) age (15–24 years, 25–44 
years); 4) living in a metropolitan statistical area (area with relatively high population 
density and economic connections), MSA (yes, principal city; yes, other MSA; not in MSA); 
and 5) born outside of the U.S. (yes, no). Measures of health care access and use included: 
1) current health insurance (private, Medicaid/Medicare, none); 2) lacked health insurance at 
any time during past 12 months (yes, no); 3) has a usual place for medical care (yes, no); and 
received prenatal care in the past 12 months (yes, no). The coding for Medicaid/Medicare 
also included military and other government health care but will be referred to as Medicaid/
Medicare. Usual place for care was included as a general measure of health care access and 
use; it was not used as a measure for having a place for prenatal care. For all variables, 
“refused” responses were coded as missing.
Analyses
We used SAS-callable (Release 9.3, SAS Institute, Cary, North Carolina) SUDAAN 
(Release 11.0.1, Research Triangle Institute, Research Triangle Park, North Carolina) for 
data analyses. Our analyses accounted for the complex sampling methods (e.g., stratification 
and clustering) used by NSFG. For all analyses, weights were also used to represent sexually 
active women aged 15–44 years living in U.S. households who were pregnant in the past 12 
months. First, among women who were pregnant at time of interview or had been pregnant 
in the past 12 months, we examined receipt of chlamydia test and receipt of other STD 
testing in the past 12 months by demographics and health care access and use. Next, we 
examined receipt of chlamydia and other STD testing among women pregnant-postpartum at 
time of interview. Wald’s chi-square tests were used for bivariate analyses, separately for 
each dependent variable. Variables with p < .25 were included in separate adjusted logistic 
regression models for received chlamydia test and received other STD test in past 12 
months. 95% confidence intervals (CI) were also calculated.
Results
Demographics
Among the 1,155 women who reported a pregnancy in the past 12 months, most (72%) were 
aged 25–44 years, half (51%) were non-Hispanic white and 45% had an income at or below 
the Medicaid expansion poverty level (Table 1). Half of pregnant women lived in a MSA but 
not the principal city, 36% lived in a principal city and 15% lived outside of a MSA. 18% 
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were born outside of the U.S. Regarding health care access, 15% of women who were 
pregnant in the past year were uninsured, 49% had private insurance and 36% had Medicaid 
or Medicare. Additionally, 23% lacked health insurance at any time during the past 12 
months, while 85% had a usual place for medical care and 75% had received prenatal care in 
the past 12 months.
Chlamydia test among women pregnant in past 12 months
Almost half (48%) of women who were pregnant in the past 12 months reported that they 
received a chlamydia test in the past 12 months (Table 2). In bivariate analyses, several 
demographic factors were significantly associated with receipt of a chlamydia test among 
these women: race/ethnicity, poverty income ratio, age, living in a MSA, and born outside of 
the U.S. Specifically, non-Hispanic black women (68.9%, 61.0–75.9) had the highest reports 
of receipt of a chlamydia test among women who were pregnant in the past 12 months. 
Younger women (15–24 years) had significantly higher reports (58.3%, 50.7–65.5) of 
chlamydia testing than women aged 25–44 years (43.6%, 38.1–49.3), and women living 
below the Medicaid expansion poverty level had higher reports (55.8%, 50.3–61.2) than 
women who had household incomes above this level (41.4%, 35.0–48.1). For living in a 
MSA, women living in the principal city of a MSA had the highest reports of receipt of 
chlamydia testing (55.6%, 49.0–62.1). Conversely, women who were born outside the U.S. 
had significantly lower reports of chlamydia testing (28.7%, 18.2–42.0) compared to those 
born in the U.S. (51.5%, 46.2–56.8). Finally, in bivariate analyses, two of the health care 
access variables were significantly associated with chlamydia testing among women who 
were pregnant in the past 12 months – current health insurance and receipt of prenatal care 
in the past 12 months. Those who had Medicaid or Medicare had the highest reports of 
chlamydia testing (63.8%, 58.1–69.2), and half of those who had received prenatal care 
(51.4%, 46.1–56.7) received a chlamydia test. All of these variables were included in an 
adjusted model.
In the adjusted model, among women who had been pregnant in the past 12 months, several 
variables continued to significantly predict receipt of a chlamydia test in the past 12 months 
(Table 4). Non-Hispanic black women (aOR=2.82, 1.86–4.26) were significantly more likely 
to receive a chlamydia test than non-Hispanic white women. As compared to women living 
in the principal city of a MSA, women living in other areas of a MSA (aOR=0.62, 0.44–
0.86) were less likely to have received a chlamydia test. Women who were born outside of 
the U.S. (aOR=0.35, 0.19–0.64) were significantly less likely than women born in the U.S. 
to have received a chlamydia test. As compared to uninsured women, those on Medicaid or 
Medicare (aOR=2.55, 1.52–4.28) were more likely to receive a chlamydia test. Finally, 
women who were pregnant in the past 12 months and reported receiving prenatal care 
(aOR=2.10, 1.35–3.28) were more likely to have received a chlamydia test than women who 
had not received prenatal care.
Other STD tests among women pregnant in past 12 months
Just over half (54%) of women who were pregnant in the past 12 months reported that they 
received a STD test other than chlamydia in the past 12 months (Table 3). In bivariate 
analyses, findings were similar to the findings for chlamydia testing with the following 
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variables being significant predictors of receipt of other STD test: race/ethnicity, poverty 
income ratio, age, living in a MSA, born outside of U.S, current health insurance and 
received prenatal care. Within subgroups containing significant differences, the highest 
reports of receipt of other STD test were for non-Hispanic black women (71.2%, 64.1–77.4), 
women with an income of < 134% of the federal poverty level (60.0%, 54.5–65.3), younger 
women (65.2%, 58.2–71.5), women who had Medicaid or Medicare (66.0%, 59.9–71.6) and 
women who had received prenatal care in the past 12 months (58.2%, 39.9–52.4). The 
lowest reports of receipt of STD test other than chlamydia, where there were significant 
differences, were for women born outside of the U.S. (34%) and women who lived in a 
MSA but not a principal city (46%).
In adjusted analyses for other STD test in past 12 months, findings were mostly similar to 
the adjusted model for chlamydia testing. Among women who were pregnant in the past 12 
months, non-Hispanic black women (aOR=2.43, 1.58–3.74) were more likely to have 
received other STD testing than non-Hispanic white women. Women living in a MSA but 
not the principal city (aOR=0.57, 0.40–0.81) were less likely to report testing than women 
living in a principal city. Also, women born outside of the U.S. (aOR=0.34, 0.20–0.58) were 
less likely to have received other STD testing than women born in the U.S. Finally, women 
who had received prenatal care in the past 12 months (aOR=2.32, 1.54–3.49) were more 
likely to have received other STD testing than women who did not receive prenatal care. 
Unlike the adjusted model for chlamydia testing, current health insurance was not a 
significant predictor of receiving other STD testing.
STD testing among women pregnant-postpartum at interview
Among women who were pregnant or postpartum at the time they were interviewed, 49.5% 
had received a chlamydia test and 58.0% had received other STD testing in the past 12 
months (refer to Table S1). Reports of testing were lowest for women who were in early 
pregnancy (32–38%), when CDC guidelines recommend screening, followed by women 
who were in late pregnancy (50–60%) and postpartum (54–62%).
Discussion
In our study, overall screening estimates for women who were pregnant or postpartum at 
interview and who had been pregnant in the past 12 months were similar. These screening 
estimates were lower than estimates from studies that use health insurance plan data and 
focus on women who received prenatal care.10,11 However, our findings included insured 
women as well as women who were uninsured and those who had health insurance but did 
not have prenatal care (e.g., women who may have been underinsured). Furthermore, our 
estimates for some subgroups are similar to those from other studies. For example, our study 
estimate for chlamydia testing among women who had Medicaid and had been pregnant in 
the past year was similar to findings from a 2013 study.18 Our study findings also expand 
those from a previous study that found prenatal syphilis screening rates to be “suboptimal” 
among insured women who had a stillbirth.12 All pregnant women should be screened for 
syphilis.8 Finally, consistent with previous research on STD testing among women on 
Medicaid by race/ethnicity,19 we found that non-Hispanic black women had higher reports 
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of chlamydia and other STD testing than other women, among those who were pregnant in 
the past year.
One of the advantages of our study is that we were able to provide national estimates of STD 
testing among pregnant women across several subpopulations. Specifically we found lower 
testing rates (chlamydia and other STD) for women who lived in MSAs but outside of the 
principal city (e.g., suburban areas) than women who lived in other areas. These results were 
somewhat surprising given research demonstrating lower access to health care in rural areas 
of the U.S than in MSAs20 and fewer health care workers in rural settings.21 Furthermore, 
one report found that persons living in suburban areas tended to have better health indicators 
than those living in other areas and had lower infant mortality rates.21 We also found that 
STD testing among women who were pregnant in the past 12 months was substantially 
lower among women who were not U.S. natives. These findings are consistent with research 
on general health care access and immigrants. In the U.S., immigrants are less likely to have 
health insurance and a usual place for health care than U.S. natives.22 A study of Latino 
immigrants in Los Angeles examined various barriers to health care access.23 Frequently 
cited barriers to care included financial issues including lacking health insurance, issues with 
communication and long delays at public clinics or hospitals.23
Our study also identified two health care access factors associated with STD testing 
including receipt of prenatal care (chlamydia and other STD test) and health insurance status 
(chlamydia test only). Our findings that pregnant women on Medicaid or Medicare were 
more likely to have received a chlamydia test than women who were uninsured were similar 
to a previous analysis of the 2006–08 NSFG that found that young women who had 
Medicaid were twice as likely as women with private insurance to have received a chlamydia 
test in the past 12 months.24 Insurance status is also important given that some populations 
(e.g., those who are not legal U.S. residents) may not qualify for Medicaid during pregnancy. 
We also found that pregnant women who had received prenatal care were more likely than 
those who did not receive prenatal care to have received chlamydia and other STD testing. 
Timely prenatal care is important for timely and appropriate prenatal syphilis screening. A 
study of pregnant women attending an emergency department who had not received prenatal 
care found an 11% syphilis prevalence among this group.25 Even pregnant women who have 
health insurance may not have timely access to care. A study in Louisiana found that the 
lack of availability of prenatal health care providers who accepted Medicaid may have led to 
delays in prenatal care.26 Some pregnant women also reported barriers in getting to prenatal 
care appointments given lack of transportation and childcare; others who obtained prenatal 
care may not have received CDC recommended screenings.26
Regardless of screening recommendations, our findings of different reports of testing among 
some subpopulations suggest that it is possible that these groups or their health care 
providers may perceive some to be at increased risk for STD. For instance, non-Hispanic 
black women are at disproportionate risk for reportable STDs in the U.S.1 Poverty, a key 
factor in eligibility for Medicaid, has also been associated with STDs.27 However, access to 
and use of care is also important with pregnant women who received prenatal services 
having higher reports of STD testing.
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Our study has some limitations. The primary limitation is that information on chlamydia and 
other STD testing was obtained via self-report which is subject to recall bias. Women may 
have been tested for chlamydia or other STDs but were not aware. This type of 
underreporting may be especially relevant for pregnant women as they may undergo 
multiple tests at the same time. It is also possible that respondents assumed that they had 
received testing when testing had not been conducted or they did not fully understand which 
STI tests they received. For example, HIV testing is also recommended for all pregnant 
women. Very few women in our analytic sample reported “don’t know” to either of our 
outcome measures but reports of “don’t know” were slightly higher for chlamydia testing 
(n=9) than other STD testing (n=7). Another limitation of our study was that the timeframe 
for our STD testing related outcome measures focused on the past 12 months rather than 
during pregnancy; thus, some testing may have occurred outside of pregnancy. The 
chlamydia and other STD testing that was reported could have been received prior to 
pregnancy for some women. Conversely, some of the women who were pregnant may not 
have obtained prenatal care prior to interview which would not have given them the 
opportunity to have received STD testing. However, our estimates for testing for women 
pregnant during the past 12 months were similar to those for women who were pregnant or 
postpartum at time of interview. Our measure of pregnancy may include women whose 
pregnancies may have ended before a first prenatal care visit. Finally, we were not able to 
include a measure that focused specifically on syphilis testing and were not able to examine 
when a woman received prenatal care in relation to when she received STD testing.
Our study of self-reported chlamydia and other STD testing among women who had been 
pregnant in the past year found less than ideal levels of recommended STD testing as all 
women should receive a test for syphilis at the first prenatal visit. Even if underreporting is 
present in our data, rates of testing are suboptimal for a population who is especially 
vulnerable to the sequelae of STDs. In the U.S., congenital syphilis has increased 153% 
from 11.6 cases per 100,000 live births in 2013 to 23.3 in 2017.1 Timely prenatal STI 
screening and appropriate treatment can prevent some poor pregnancy and birth outcomes. 
Interventions may be needed to increase awareness of CDC’s STD testing recommendations 
among pregnant women and health care providers. Departments of health and other public 
health programmes may want to provide targeted interventions or education to providers 
who see a high volume of pregnant women. Our findings also highlight the importance of 
obtaining prenatal care to receive recommended STD screenings during pregnancy.
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Table 1.
Demographics and health care access among women who were pregnant in the past 12 
months, 2011–15 (n=1155)
Note. Percentages are weighted. CI = confidence interval. Ns for each variable may not total 1155 due to 
missing values. MSA is an area with relatively high population density and economic connections.
N % (95% CI)
Overall
Demographics
Race/ethnicity
 Hispanic/Latino 323 22.9 (19.1–27.2)
 Non-Hispanic white 460 50.9 (46.2–55.6)
 Non-Hispanic black 302 18.8 (15.5–22.5)
 Non-Hispanic other 70 7.4 (5.0–10.9)
Poverty income ratio
 0–133% 607 44.9 (40.2–49.8)
 134% or higher 548 55.1 (50.2–59.9)
Age
 15–24 years 365 28.2 (24.3–32.3)
 25–44 years 790 71.9 (67.7–75.7)
Metropolitan statistical area (MSA)
 Yes, principal city of MSA 482 35.5 (30.0–41.4)
 Yes, other MSA 497 49.7 (43.4–56.1)
 Not MSA 176 14.8 (11.0–19.7)
Born outside of the U.S.
 Yes 207 17.5 (14.2–21.5)
 No 948 82.5 (78.5–85.8)
Health care access
Current health insurance
 Private 451 49.3 (44.1–54.4)
 Medicaid or Medicare 530 36.2 (31.9–40.9)
 None 174 14.5 (11.5–18.0)
Lacked health insurance at any time (past 12 months)
 Yes 282 22.7 (19.2–26.6)
 No 873 77.3 (73.4–80.8)
Has a place for usual medical care
 Yes 959 85.3 (82.1–88.1)
 No 196 14.7 (11.9–17.9)
Received prenatal service in past 12 months
 Yes 841 75.2 (70.9–79.1)
 No 313 24.8 (20.9–29.2)
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Table 2.
Receipt of chlamydia test (past 12 months) among women who were pregnant in past 12 
months by demographics and health care access, 2011–15 (n=1129)
Data are weighted and presented as % (95%CI). CI = confidence interval. MSA is an area with relatively high 
population density and economic connections.
Received chlamydia test Did not receive
chlamydia test
P value
Overall 47.8 (43.2–52.4) 52.2 (47.6–56.8)
Demographics
Race/ethnicity <0.001
 Hispanic/Latino 48.2 (38.7–57.8) 51.8 (42.2–61.3)
 Non-Hispanic white 42.3 (36.0–48.9) 57.7 (51.1–64.0)
 Non-Hispanic black 68.9 (61.0–75.9) 31.1 (24.1–39.0)
 Non-Hispanic other 29.7 (17.5–45.8) 70.3 (54.2–82.5)
Poverty income ratio 0.001
 0–133% 55.8 (50.3–61.2) 44.2 (38.8–49.7)
 134% or higher 41.4 (35.0–48.1) 58.6 (51.9–65.0)
Age 0.003
 15–24 years 58.3 (50.7–65.5) 41.7 (34.5–49.3)
 25–44 years 43.6 (38.1–49.3) 56.4 (50.7–62.0)
Metropolitan statistical area (MSA) 0.003
 Yes, principal city of MSA 55.6 (49.0–62.1) 44.4 (37.9–51.0)
 Yes, other MSA 40.5 (34.4–46.9) 59.5 (53.1–65.6)
 Not MSA 53.3 (42.5–63.8) 46.7 (36.2–57.5)
Born outside of the U.S. <0.001
 Yes 28.7 (18.2–42.0) 71.4 (58.0–81.8)
 No 51.5 (46.2–56.8) 48.5 (43.2–53.8)
Health care access
Current health insurance <0.001
 Private 39.6 (32.7–46.9) 60.4 (53.1–67.3)
 Medicaid or Medicare 63.8 (58.1–69.2) 36.2 (30.8–41.9)
 None 36.8 (28.6–46.0) 63.2 (54.0–71.4)
Lacked health insurance at any time (past 12 months) 0.289
 Yes 43.7 (36.3–51.3) 56.3 (48.7–63.7)
 No 49.0 (43.4–54.6) 51.0 (45.4–56.7)
Has a place for usual medical care 0.396
 Yes 48.4 (43.3–53.5) 51.6 (46.5–56.7)
 No 44.1 (35.4–53.1) 55.9 (46.9–64.6)
Received prenatal service (past 12 months) 0.008
 Yes 51.4 (46.1–56.7) 48.6 (43.3–54.0)
 No 37.0 (29.1–45.7) 63.0 (54.3–70.9)
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Table 3.
Receipt of any STD testing other than chlamydia (past 12 months) among women who 
were pregnant in the past 12 months by demographics and health care access, 2011–15 
(n=1136)
Data are weighted and presented as % (95%CI). CI = confidence interval. MSA is an area with relatively high 
population density and economic connections.
Received STD test
other than
chlamydia
Did not receive STD
test other than
chlamydia
P value
Overall 53.9 (49.3–58.4) 46.1 (41.6–50.7) --
Demographics
Race/ethnicity <.001
 Hispanic/Latino 55.3 (47.4–62.9) 44.8 (37.1–52.6)
 Non-Hispanic white 49.5 (42.6–56.4) 50.6 (43.7–57.4)
 Non-Hispanic black 71.2 (64.1–77.4) 28.8 (22.6–35.9)
 Non-Hispanic other 34.9 (22.6–49.6) 65.1 (50.4–77.4)
Poverty income ratio .018
 0–133% 60.0 (54.4–65.3) 40.1 (34.7–45.6)
 134% or higher 49.0 (42.3–55.8) 51.0 (44.2–57.7)
Age <.001
 15–24 years 65.2 (58.2–71.5) 34.8 (28.5–41.8)
 25–44 years 49.4 (43.8–55.0) 50.6 (45.0–56.2)
Metropolitan statistical area (MSA) .002
 Yes, principal city of MSA 62.1 (55.9– 67.9) 37.9 (32.1–44.1)
 Yes, other MSA 46.1 (39.9–52.4) 53.9 (47.6–60.1)
 Not MSA 60.1 (47.8–71.2) 39.9 (28.8–52.2)
Born outside of the U.S. <.001
 Yes 34.0 (24.4–45.1) 66.0 (54.9–75.6)
 No 57.8 (52.4–63.0) 42.2 (37.0–47.6)
Health care access
Current health insurance <.001
 Private 47.4 (40.0–55.0) 52.6 (45.1–60.0)
 Medicaid or Medicare 66.0 (59.9–71.6) 34.0 (28.4–40.1)
 None 46.7 (36.2–57.5) 53.3 (42.5–63.8)
Lacked health insurance at any time (past 12 months)
 Yes 54.5 (46.0–62.9) 45.5 (37.2–54.0) .870
 No 53.7 (48.2–59.1) 46.3 (40.9–51.8)
Has a place for usual medical care .651
 Yes 53.5 (48.6–58.3) 46.5 (41.7–51.4)
 No 56.1 (45.5–66.2) 43.9 (33.9–54.5)
Received prenatal service (past 12 months) .001
 Yes 58.2 (53.4–62.9) 41.8 (37.1–46.7)
 No 40.9 (32.6–49.7) 59.1 (50.3–67.4)
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Table 4.
Adjusted analyses for receipt of chlamydia testing and receipt of STD testing other than 
chlamydia (past 12 months) among women who were pregnant in the past 12 months, 
2011–15
Data are presented as aOR (95%CI). Note. ref = reference group. aOR = adjusted odds ratio. CI = confidence 
interval. MSA is an area with relatively high population density and economic connections.
Received chlamydia test
(n=1129)
Received STD test other than
chlamydia
(n=1136)
Demographics
Race/ethnicity
 Hispanic/Latino 1.47 (0.90–2.42) 1.52 (0.99–2.33)
 Non-Hispanic white (ref) 1.00 1.00
 Non-Hispanic black 2.82 (1.86–4.26) 2.43 (1.58–3.74)
 Non-Hispanic other 0.92 (0.49–1.71) 0.88 (0.47–1.66)
Poverty income ratio
 0–133% 1.37 (0.92–2.06) 1.24 (0.82–1.85)
 134% or higher (ref) 1.00 1.00
Age
 15–24 years 1.05 (0.70–1.59) 1.24 (0.86–1.79)
 25–44 years (ref) 1.00 1.00
Metropolitan statistical area (MSA)
 Yes, principal city of MSA (ref) 1.00 1.00
 Yes, other MSA 0.62 (0.44–0.86) 0.57 (0.40–0.81)
 Not MSA 0.87 (0.51–1.49) 0.84 (0.46–1.53)
Born outside of the U.S.
 Yes 0.35 (0.19–0.64) 0.34 (0.20–0.58)
 No (ref) 1.00 1.00
Health care access
Current health insurance
 Private 1.39 (0.87–2.23) -- --
 Medicaid or Medicare 2.55 (1.52–4.28) -- --
 None (ref) 1.00 -- --
Received prenatal service (past 12 months)
 Yes 2.10 (1.35–3.28) 2.32 (1.54–3.49)
 No (ref) 1.00 1.00
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